|
Match
|
Document |
Document Title |
|
|
7311910 |
Methods for treating cancer and infectious disease by blocking CTLA4-B7 interactions
The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing...
|
|
|
7311911 |
Methods for inhibiting angiogenesis
The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting α5β1 integrin in the tissue with an agent that interferes with the specific binding of...
|
|
|
7309489 |
Mouse CD40 ligand-specific antibodies and hybridomas
There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human...
|
|
|
7306795 |
PRO5774 antibodies
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7306800 |
Treatment of autoimmune disorders with antibodies to costimulating polypeptide of T cells
A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against the 8F4 molecule and hybridoma cells which produce the monoclonal...
|
|
|
7306798 |
Immunoglobulin IgG3 as a marker for protecting against infectious viral diseases, and the uses of the same
The invention relates to a novel variant of isolated and/or purified immunoglobulin IgG3 which can be used as a marker for protecting against infectious viral diseases such as AIDS, as a diagnostic...
|
|
|
7306797 |
Use of a compound antagonist of ESM-1 protein for producing a medicine for treating cancer
Use of an antagonist compound of protein ESM-1 for the production of a drug for the treatment of a cancer.
|
|
|
7306807 |
Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease
The present invention relates to a novel, isolated and purified hemorrhagic feline calicivirus FCV-DD1. The invention further embraces monovalent and multivalent vaccines containing the new FCV-DD1...
|
|
|
7304144 |
Antibodies binding to human TSLP Polypeptides
The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides,...
|
|
|
7303914 |
Monoclonal antibody against human hepatoma and use thereof
The present invention provides a monoclonal antibody MF4C4 against human hepatoma marker antigen. This monoclonal antibody is characterized by high specifically binding to the hepatoma antigen. The...
|
|
|
7297336 |
Factor IXa specific antibodies displaying factor VIIIa like activity
Ligands such as antibodies that can bind factor IX/factor IXa and increase the procoagulant activity of factor IXa (FIXa), pharmaceutical compositions containing such ligands, methods for treating...
|
|
|
7294704 |
Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
This invention relates to a method for assessing risk of prostate cancer. Specifically, it relates to utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination to determine the risk...
|
|
|
7294335 |
PRO19645 antibodies
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7294336 |
Stabilized liquid anti-RSV antibody formulations
The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which...
|
|
|
7291334 |
Antibodies to novel proteins in enteroaggregative Escherichia coli (EAEC) useful for diagnosis and therapy of EAEC infections
Novel proteins and their corresponding nucleotide sequences in enteroaggregative Escherichia coli (EAEC) are provided. In particular, Aap and the five gene cluster (aat) of the AA probe region of...
|
|
|
7291329 |
Antibodies against PRO4406
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7288249 |
Antibodies for cancer therapy and diagnosis
The present application describes a method for making antibodies which can be used for cancer diagnosis or therapy. The application also discloses a method for identifying an antigen which is...
|
|
|
7288247 |
Antibodies for use in targeted and temporary treatment of humans and animals
An antibody or an antibody fragment that binds to an epitope under specifically chosen conditions; the binding of which to the epitope is broken under specifically chosen different conditions....
|
|
|
7288638 |
Fully human antibodies against human 4-1BB
Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody....
|
|
|
7288251 |
Antibodies to CD40
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also...
|
|
|
7288252 |
Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies
Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment...
|
|
|
7285267 |
Tumor necrosis factor receptors 6α & 6β
The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6α & -6β proteins. TNFR-6α &...
|
|
|
7282567 |
Monoclonal antibody hPAM4
This invention relates to monovalent and multivalent, monospecific antibodies and to multivalent, multispecific antibodies. One embodiment of these antibodies has one or more identical binding...
|
|
|
7282204 |
Uses of IL-23 agonists and antagonists; related reagents
Provided are methods of treatment for tumors. In particular, methods are provided for modulating activity of a cytokine molecule and its receptor.
|
|
|
7282206 |
Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
Methods are provided for treating or inhibiting the formation of tissue fibrosis using IL-13 antagonists, including without limitation soluble forms of the IL-13 receptor.
|
|
|
7282205 |
Anti-hepatitis A virus antibodies
Chimpanzee monoclonal antibodies and antigen binding fragments including a γ1-chain CDR3 region that bind hepatitis A virus (HAV) antigen are disclosed herein. The antibodies neutralize HAV. Also...
|
|
|
7282203 |
Use of NOTCH pathway interfering agents for treatment of plasma cell disorders
The present invention provides a method for reducing the severity of, or treatment of, plasma cell disorders. The method comprises the step of administering to an individual afflicted with a plasma...
|
|
|
7279157 |
Method for treating psoriasis by administering an anti-il-12 antibody
The present invention relates to an anti-IL-12 antibody, including isolated nucleic acids that encode an anti-IL-12 antibody, IL-12, vectors, host cells, transgenic animals or plants, and methods...
|
|
|
7279158 |
Methods for the treatment of inflammatory joint disease
The use of compounds that block complement component C5 or its active fragments C5 a and/or C5 b (such compounds collectively referred to as “C5 blockers”) to treat established joint...
|
|
|
7276238 |
Methods for using chemokine teck
Novel chemokines from mammals, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said chemokines. Chemokine receptors are also provided. Methods...
|
|
|
7276239 |
Recombinant A2-specific TNFα-specific antibodies
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated...
|
|
|
7273924 |
Antibodies to the ED-B domain of fibronectin, their construction and uses
A specific binding member is specific for and binds directly to the ED—B oncofoetal domain of fibronectin (FN).
|
|
|
7271245 |
Methods and compositions for inhibition of metastasis
This invention generally relates to methods of producing an antibody phage population having affinity for a tumor cell target expressing a metastatic phenotype. The invention further relates to...
|
|
|
7267819 |
Composition comprising and method of using angiopoietin-like protein 3 Angptl3
The present invention is directed to methods and means for making and using Angptl3 polypeptides. The invention specifically concerns the use of Angptl3 polypeptides in inducing liver regeneration...
|
|
|
7264805 |
Proteins with a high immunoreactivity and a method for the production thereof
The invention relates to (glyco-) proteins, in particular monoclonal antibodies, which have an immunoreactivity of >81%, preferably >90%. The inventive monoclonal antibodies are produced...
|
|
|
7264801 |
EG-VEGF nucleic acids and polypeptides and method of use
The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells...
|
|
|
7264803 |
Methods and pharmaceutical formulations for the treatment of pulmonary hypertension
A method of treating pulmonary hypertension in a subject in need of such treatment comprises inhibiting EMAP II activity in the subject by an amount effective to treat the pulmonary hypertension in...
|
|
|
7262277 |
Antagonistic anti-hFAS ligand human antibodies and fragments thereof
Human antibodies, preferably recombinant human antibodies that specifically bind to human Fas Ligand (hFasL) are disclosed. These antibodies have high affinity for hFasL, a slow off rate for hFasL...
|
|
|
7261890 |
Methods for using canine immunoglobulin variable domains and caninized antibodies
The present invention provides canine heavy chain and light chain (both λ and κ) variable domain nucleic acids and polypeptides. The present invention also provides caninized antibodies comprised...
|
|
|
7261893 |
Neutralizing antibodies against GDF-8 and uses therefor
The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in...
|
|
|
7259247 |
Anti-human T-cell costimulating polypeptide monoclonal antibodies
A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against said 8F4 molecule and hybridoma cells which produce the...
|
|
|
7256273 |
Humanized antibodies that recognize beta amyloid peptide
The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.
|
|
|
7255859 |
Monoclonal antibodies against the epitope YPYDVPDYA, a process for their production and their use
The invention concerns monoclonal antibodies against the epitope YPYDVPDYA (SEQ ID NO: 1) which is derived from the haemagglutinin of the human influenza virus and are suitable for the detection...
|
|
|
7253263 |
Complementarity determining region-grafted antibody against ganglioside GD3 and derivative of antibody against ganglioside GD3
The present invention relates to a human CDR-grafted antibody against ganlioside GD3 (hereinafter referred to “GD3”), derivatives of an anti-GD3 antibody and cytokine, and use for treatment and...
|
|
|
7250494 |
Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
The present invention encompasses monoclonal antibodies that bind to lipoteichoic acid (LTA) of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and...
|
|
|
7247304 |
Methods of treating using anti-IL-15 antibodies
Isolated human monoclonal antibodies which specifically bind to IL-15 (e.g., human IL-15), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced...
|
|
|
7247302 |
Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
The present invention provides a method for inhibiting immunoglobulin-induced toxicity resulting from immunotherapy in a subject comprising administering an immunoglobulin or Ig fusion protein...
|
|
|
7247303 |
Selected antibody CDRs for binding to aminophospholipids
Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for...
|
|
|
7247453 |
Calcium binding recombinant antibody against protein C
A Ca 2+ dependent recombinant antibody that specifically binds to a specific twelve peptide sequence (E D Q V D P R L I D G K) in the activation region of the Protein C has been constructed. The...
|
|
|
7244428 |
PRO1357 antibodies
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|